The patent landscape for risperidone, an antipsychotic medication, has evolved significantly since its initial introduction. Understanding risperidone's patent status is crucial for assessing market entry for generic versions and potential patent challenges.
When does risperidone patent exclusivity expire?
Risperidone was first approved in the United States in 1993 [1]. The primary patents covering risperidone expired years ago, allowing for the introduction of generic versions of the oral formulation. For instance, the main compound patent expired in 2007 [2]. However, extended-release formulations and other specific delivery methods may have had later-expiring patents. DrugPatentWatch.com provides detailed information on patent expiry dates for various drug formulations and regions [3].
What are the key patents related to risperidone?
The original patents for risperidone focused on the chemical compound itself. As the drug matured, patents were also granted for manufacturing processes, specific polymorphic forms, and different delivery systems, such as long-acting injectable formulations. These later patents could provide periods of extended market exclusivity beyond the expiry of the core compound patent.
Can biosimilars or generics enter the market?
Generic versions of oral risperidone are already available on the market. The expiry of key patents opened the door for these lower-cost alternatives. For injectable extended-release risperidone, the situation is more complex, and market entry for generics or biosimilars would depend on the expiry of patents specifically covering those formulations and their manufacturing.
Who are the main manufacturers of risperidone?
The originator of risperidone was Janssen Pharmaceutica, a subsidiary of Johnson & Johnson. Following patent expiries, numerous generic pharmaceutical companies now manufacture and market risperidone, making it widely accessible.
What is the current patent litigation surrounding risperidone?
Given that the primary patents have expired, significant new patent litigation directly challenging the core risperidone compound patent is unlikely. However, disputes could arise concerning patents for newer formulations, manufacturing methods, or potential secondary uses of the drug. Information on ongoing patent litigation can often be found through specialized legal and pharmaceutical databases.